Derivation and Validation of a Necroptosis-Related lncRNA Signature in Patients with Ovarian Cancer

Figure 9

The sensitivity of chemotherapeutic medicines in different risk groups. (a) Paclitaxel. (b) Gemcitabine. (c) Etoposide. (d) Docetaxel. (e) Doxorubicin. (f) Cisplatin.

(a)

(b)

(c)

(d)

(e)

(f)